review Open AccessTop 1% cited
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
European Heart Journal · 2017 · Vol. 38(32) · pp. 2459–2472
Brian A. Ference✉(Wayne State University)Henry N. Ginsberg(Columbia University)Ian Graham(Trinity College Dublin)Kausik K. Ray(Primary Health Care)Chris J. Packard(University of Glasgow)Éric Bruckert(Inserm)Robert A. Hegele(Western University)Ronald M. KraussFrederick J. Raal(University of the Witwatersrand)Heribert Schunkert(German Centre for Cardiovascular Research)Gerald F. Watts(The University of Western Australia)Jan Borén(Sahlgrenska University Hospital)Sergio Fazio(Oregon Health & Science University)Jay D. Horton(The University of Texas Southwestern Medical Center)L. Masana(Universitat Rovira i Virgili)Stephen J. Nicholls(South Australian Health and Medical Research Institute)Børge G. Nordestgaard(University of Copenhagen)Bart van de Sluis(University Medical Center Groningen)Marja‐Riitta Taskinen(University of Helsinki)Lâle Tokgözoğlu(Hacettepe University)Ulf Landmesser(Inserm)Ulrich Laufs(Universitätsklinikum des Saarlandes)Olov Wiklund(Sahlgrenska University Hospital)Jane K. Stock(European Atherosclerosis Society)M. John Chapman(Inserm)Alberico L. Catapano(University of Milan)
Abstract
Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismDiabetes, Cardiovascular Risks, and LipoproteinsMedicineConsensus conferenceAtherosclerotic cardiovascular diseaseStatement (logic)DiseaseInternal medicineCardiologyLaw
MeSH terms
EzetimibeProprotein Convertase 9PCSK9 InhibitorsAnticholesteremic AgentsEpidemiologic MethodsHyperlipidemiasCholesterol, HDLLipoproteins, LDLCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsGenetic Predisposition to DiseaseConsensusAtherosclerosis
Funding
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Alnylam Pharmaceuticals
- Danone
- CSL Behring
- Regeneron Pharmaceuticals
- Amarin Corporation
- Anthera
- Medicines Company
- Kowa Company
- Mylan
- InfraRedx
- Daiichi-Sankyo
- Novo Nordisk
- Servier
- Esperion Therapeutics
- Bayer Vital
Citations
3,678
FWCI
234.38
field-weighted impact
References
60
Percentile
100%
vs. same field & year
Citations per year
Cited by
Gut Microbiome: Profound Implications for Diet and Disease
Nutrients · 2019 · 1,090 citations
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
European Heart Journal · 2021 · 5,933 citations
Pathophysiology of Type 2 Diabetes Mellitus
International Journal of Molecular Sciences · 2020 · 2,963 citations
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Circulation · 2023 · 5,692 citations
Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases
Frontiers in Immunology · 2019 · 861 citations
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Circulation · 2022 · 5,901 citations
2024 ESC Guidelines for the management of chronic coronary syndromes
European Heart Journal · 2024 · 1,953 citations
2023 ESC Guidelines for the management of acute coronary syndromes
European Heart Journal · 2023 · 4,023 citations
References
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Statistics in Medicine · 2007 · 4,904 citations
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
Circulation · 2013 · 7,098 citations
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
European Heart Journal · 2016 · 3,169 citations
Discovery and refinement of loci associated with lipid levels
Nature Genetics · 2013 · 3,254 citations
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
The Lancet · 2004 · 11,852 citations
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
The Lancet · 2010 · 6,335 citations
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
European Heart Journal · 2013 · 2,699 citations
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
Nature Genetics · 2015 · 2,673 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.